Grifols signs agreement with Stough Development Corporation to open 10 new plasma collection Centers in the United States

**Barcelona, 12 March 2008:** Grifols, the Spanish holding company specializing in the pharmaceutical-hospital sector and the world’s fourth-largest producer of plasma products, has signed an agreement with Stough Development Corporation, the former owner of PlasmaCare Inc. (acquired by Grifols two years ago), under which the US company will construct and lease to Grifols 10 new plasma collection centers in the United States within a period of approximately 18 months.

As a result, the Spanish group expects to obtain an additional 400,000 of its main raw material, without allocating any internal resources to this, as the operation will be financed in fully by Stough Development Corporation as the owner and lessor of the centers, which will be operated by Grifols on a leasing basis.

The plasmapheresis centers will be built from scratch, following a model approved by both companies, and will be delivered to Grifols on a “turnkey” basis, so that they will be fully equipped and will already have the corresponding permits and licenses.

For Shinji Wada, president of the company responsible for Grifols’ plasma collection centers, “this agreement will allow us to increase the supply of plasma for fractionation. It will also free up human resources and, thanks to the agreed formula, will also release considerable financial resources.”

“At the same time, the arrangement entered into with Stough Development Corporation, the former owner of PlasmaCare Inc., is a powerful guarantee for us as, thanks to their experience in the sector, they have both the knowledge and the technical and human resources to implement this project.”

This contract is included in the investment plan approved by Grifols last October.
Grifols is the second largest company in the world in terms of plasma collection capacity

In 2007 Grifols collected 22% more plasma than in 2006 thanks to the inclusion of 4 new plasma collection centers and the extension of already-existing centers. Today, the group has 77 plasmapheresis centers and collects over 2 million liters of plasma per year for fractionation and conversion into hemoderivatives. Grifols is the second largest company in the world in terms of plasma collection capacity.

Despite this, the Spanish group plans to continue strengthening its access to raw materials both by expansion of its operations and through acquisitions, as it analyzes and evaluates any opportunities which may arise in the market. In accordance with the investment plan for the period 2008-2012, the increase in raw material will be accompanied by an increase in fractionation capacity over the next few years.

About Grifols

Grifols is a Spanish holding company specialized in the pharmaceutical-hospital sector and is present in more than 90 countries. Since 2006, the company has been listed on the Spanish Mercado Continuo and forms part of the Ibex-35. Currently it is the first company in the European plasma derivatives sector and the fourth in production worldwide. In upcoming years, the company will strengthen its leadership in the industry as a vertically integrated company, thanks to recent investments and those which will be carried out in 2008-2012, representing 400 million euros. In terms of raw materials, Grifols has ensured its plasma supply with 77 plasmapheresis centers in the United States and in terms of fractionation, its plants in Barcelona (Spain) and Los Angeles (United States) will allow the company to respond to the growing market demand. Nevertheless, the company is preparing for sustained growth in the following 8-10 years and has launched an ambitious investment plan.